Ameriprise Financial Inc. Acquires 25,167 Shares of Danaher Corporation $DHR

Key Points

• Ameriprise Financial Inc. increased its stake in Danaher Corporation by 3.6%, now owning 716,147 shares worth approximately $146.83 million.
• Danaher reported earnings of $1.80 per share, exceeding expectations and showing a 3.4% revenue increase year-over-year with total revenue hitting $5.94 billion.
• Seventeen investment analysts have rated Danaher with a consensus rating of "Moderate Buy", predicting a price target of $247.61.

Ameriprise Financial Inc. increased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 3.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 716,147 shares of the conglomerate's stock after acquiring an additional 25,167 shares during the quarter. Ameriprise Financial Inc. owned about 0.10% of Danaher worth $146,834,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after buying an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Danaher by 3.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after purchasing an additional 612,154 shares during the period. Bank of New York Mellon Corp raised its position in shares of Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after purchasing an additional 194,466 shares during the period. Northern Trust Corp raised its position in shares of Danaher by 14.3% during the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock worth $1,821,477,000 after purchasing an additional 992,594 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Danaher by 11.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock worth $1,303,163,000 after buying an additional 579,046 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 0.2%

Shares of DHR stock traded up $0.42 during mid-day trading on Thursday, hitting $205.42. The company's stock had a trading volume of 1,557,658 shares, compared to its average volume of 4,178,820. The stock has a market cap of $147.09 billion, a price-to-earnings ratio of 43.66, a PEG ratio of 2.88 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The business has a 50-day moving average price of $201.23 and a 200 day moving average price of $199.46.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DHR. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a report on Friday, July 11th. Robert W. Baird upped their price target on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Guggenheim reiterated a "buy" rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, July 23rd. Wells Fargo & Company decreased their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Finally, Barclays reiterated an "overweight" rating and set a $225.00 price target (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $247.61.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 11.10% of the stock is currently owned by insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.